Physician profile
Pierre Moeser
NPI 1063452787
$1,253.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.85 · 2020: $72.55 · 2021: $184 · 2022: $573 · 2023: $280 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.29 | 2020-2023 | |
| Glaxosmithkline, LLC. | $174.55 | 2019-2023 | Benlysta |
| Janssen Biotech, INC. | $172.15 | 2020-2023 | Tremfya, Stelara, Remicade |
| Nevro Corp. | $129.49 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $122.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.24 | 2022 | |
| Horizon Therapeutics Plc | $57.62 | 2022-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $31.07 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $22.43 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.42 | 2023 | Saphnelo |
| Pfizer INC. | $16.76 | 2020 | |
| Sandoz INC. | $13.55 | 2023 | |
| Ucb, INC. | $13.07 | 2023 | Cimzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Moeser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.